FR2744447B1 - Utilisation de derives de tetrahydroisoquinoleine - Google Patents

Utilisation de derives de tetrahydroisoquinoleine

Info

Publication number
FR2744447B1
FR2744447B1 FR9701081A FR9701081A FR2744447B1 FR 2744447 B1 FR2744447 B1 FR 2744447B1 FR 9701081 A FR9701081 A FR 9701081A FR 9701081 A FR9701081 A FR 9701081A FR 2744447 B1 FR2744447 B1 FR 2744447B1
Authority
FR
France
Prior art keywords
tetrahydroisoquinolein
derivatives
tetrahydroisoquinolein derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9701081A
Other languages
English (en)
Other versions
FR2744447A1 (fr
Inventor
Alexander Alanine
Anne Bourson
Bernd Buttelmann
Gunther Fischer
Neidhart Marie Paule Heitz
Vincent Mutel
Emmanuel Pinard
Stephan Rover
Gerhard Trube
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2744447A1 publication Critical patent/FR2744447A1/fr
Application granted granted Critical
Publication of FR2744447B1 publication Critical patent/FR2744447B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR9701081A 1996-02-03 1997-01-31 Utilisation de derives de tetrahydroisoquinoleine Expired - Fee Related FR2744447B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96101553 1996-02-03

Publications (2)

Publication Number Publication Date
FR2744447A1 FR2744447A1 (fr) 1997-08-08
FR2744447B1 true FR2744447B1 (fr) 2000-09-29

Family

ID=8222462

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9701081A Expired - Fee Related FR2744447B1 (fr) 1996-02-03 1997-01-31 Utilisation de derives de tetrahydroisoquinoleine

Country Status (29)

Country Link
US (2) US5952344A (fr)
JP (1) JP3217290B2 (fr)
KR (1) KR100229298B1 (fr)
CN (1) CN1167762A (fr)
AR (1) AR005613A1 (fr)
AU (1) AU723586B2 (fr)
BR (1) BR9700816A (fr)
CA (1) CA2196392A1 (fr)
CO (1) CO4761069A1 (fr)
CZ (1) CZ29497A3 (fr)
DE (1) DE19703985A1 (fr)
ES (1) ES2124672B1 (fr)
FR (1) FR2744447B1 (fr)
GB (1) GB2309642A (fr)
HR (1) HRP970060A2 (fr)
HU (1) HUP9700273A1 (fr)
ID (1) ID15866A (fr)
IL (1) IL120100A (fr)
IT (1) IT1289621B1 (fr)
MA (1) MA24078A1 (fr)
NO (1) NO970431L (fr)
NZ (1) NZ314130A (fr)
PE (1) PE35698A1 (fr)
PL (1) PL318256A1 (fr)
SG (1) SG55273A1 (fr)
TR (1) TR199700071A2 (fr)
TW (1) TW427978B (fr)
YU (1) YU3997A (fr)
ZA (1) ZA97672B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
AU2008272964A1 (en) * 2007-06-29 2009-01-08 Emory University NMDA receptor antagonists for neuroprotection
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3217007A (en) * 1965-11-09 Halo- and nitro-substituted phenethyl-z- methyl tetrahydroisoquinolsnes
US3067203A (en) * 1962-12-04 Tetrahybroisqquinoline derivatives
NL286505A (fr) * 1961-12-15
CH418336A (de) * 1962-02-23 1966-08-15 Hoffmann La Roche Verfahren zur Herstellung von Octahydrophenanthridinverbindungen
US3243438A (en) * 1962-02-23 1966-03-29 Hoffmann La Roche Octahydro phenanthridine compounds
US3480714A (en) * 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
US3361767A (en) * 1966-04-04 1968-01-02 American Home Prod 10, 5(epoxymethano)-10, 11-dihydro-5h-dibenzo[a, d]cyclohepten-13-one and derivatives
GB1386076A (en) * 1971-06-03 1975-03-05 Wyeth John & Brother Ltd Isoquinoline derivatives
US3803151A (en) * 1972-08-23 1974-04-09 Bristol Myers Co Synthesis for the preparation of 3-hydroxy-n-alkylisomorphinans
JPS5291868A (en) * 1976-01-26 1977-08-02 Takeda Chem Ind Ltd Indenopyridine derivatives
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
DE3664768D1 (en) * 1985-12-13 1989-09-07 Lafon Labor 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives, preparation process and medicinal use
ES2061972T3 (es) * 1988-02-19 1994-12-16 Smithkline Beecham Farma 1,2,3,4-tetrahidroisoquinoleinas, procedimiento para su preparacion y su uso como agonistas kapa-receptores.
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
BR9106432A (pt) * 1990-05-10 1993-05-04 Pfizer Indolona neuroprotetora e derivados correlatos
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JPH0741481A (ja) * 1993-05-21 1995-02-10 Hokuriku Seiyaku Co Ltd 両性型三環系化合物
US5389638A (en) * 1993-09-10 1995-02-14 Abbott Laboratories Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors
US5439915A (en) * 1994-10-20 1995-08-08 American Home Products Corporation Pyrido[3,4-B]indole carboxamide derivatives as serotonergic agents
US5605906A (en) * 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof

Also Published As

Publication number Publication date
HUP9700273A1 (hu) 1999-08-30
KR970061871A (ko) 1997-09-12
US5952344A (en) 1999-09-14
DE19703985A1 (de) 1997-10-30
CZ29497A3 (en) 1997-08-13
BR9700816A (pt) 1998-07-07
NZ314130A (en) 1998-04-27
ID15866A (id) 1997-08-14
HU9700273D0 (en) 1997-03-28
CO4761069A1 (es) 1999-04-27
ZA97672B (en) 1997-08-04
PE35698A1 (es) 1998-07-16
AR005613A1 (es) 1999-06-23
CA2196392A1 (fr) 1997-08-04
CN1167762A (zh) 1997-12-17
IL120100A0 (en) 1997-04-15
HRP970060A2 (en) 1998-04-30
IL120100A (en) 2001-01-28
AU723586B2 (en) 2000-08-31
PL318256A1 (en) 1997-08-04
IT1289621B1 (it) 1998-10-15
US6071929A (en) 2000-06-06
NO970431L (no) 1997-08-04
KR100229298B1 (ko) 1999-11-01
FR2744447A1 (fr) 1997-08-08
NO970431D0 (no) 1997-01-31
AU1233597A (en) 1997-08-07
TW427978B (en) 2001-04-01
MA24078A1 (fr) 1997-10-01
SG55273A1 (en) 1998-12-21
GB9702049D0 (en) 1997-03-19
ES2124672A1 (es) 1999-02-01
JP3217290B2 (ja) 2001-10-09
ITMI970153A1 (it) 1998-07-28
ES2124672B1 (es) 1999-11-16
GB2309642A (en) 1997-08-06
YU3997A (sh) 1999-09-27
TR199700071A2 (tr) 1997-08-21
JPH09221474A (ja) 1997-08-26

Similar Documents

Publication Publication Date Title
PT934320E (pt) Derivados de naftiridina
BR9708386A (pt) Derivados de 6-fenilpiridil-2-amina
DE69735712D1 (de) Aryl-pyrimidin-derivate
MA24168A1 (fr) Utilisation de derives de benzofuryle
BR9507179A (pt) Derivados de 3-aril-4-hidróxi-delta3-dihidrotiofena
DE69716296T2 (de) Indan- oder dihydroindolderivate
DK0946547T3 (da) Hidtil ukendt forbindelsesform
EE9800219A (xx) Uued 19-nor-pregneeni derivaadid
DE69720051D1 (de) Harnstoffderivate
BR9712037A (pt) Derivados de piperazina
NO981946D0 (no) Imidazoquinazolin-derivater
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
BR9709065A (pt) Derivados de alquilaminobenzotiazole e-benzoxazol
EE9900182A (et) 2-metoksüfenüülpiperasiini derivaadid
MA23794A1 (fr) Utilisation de phenylcyclohexylcarboxamides
PT931087E (pt) Novos derivados de piranosido
PT906279E (pt) Derivados de pirrol
MA26480A1 (fr) Derives de phenoxymethylpiperidine
MA26440A1 (fr) Derives de n-benzylazolium
FR2744447B1 (fr) Utilisation de derives de tetrahydroisoquinoleine
BR9708310A (pt) Derivados de 2-tioxotetrahidropirimidin-4-ona
BR9706980A (pt) Derivados de isooxacefem
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
BR9704770A (pt) Derivados de 1-carba-(detia)-cefalosporina

Legal Events

Date Code Title Description
ST Notification of lapse